NCT05061901View on ClinicalTrials.gov

Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

November 6, 2021

Study Completion Date

November 6, 2021

Conditions

Bioequivalence

Interventions

DRUG

Lisinopril tablet 20 mg

Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.

DRUG

Zestril® tablet 20 mg

Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.

Trial Locations (1)

150047

"Private healthcare institution Clinical Hospital RZD-Medicine of the city of Yaroslavl", Yaroslavl

All Listed Sponsors

collaborator

ClinPharmInvest, LLC

OTHER

lead

Pharmtechnology LLC

INDUSTRY

NCT05061901 - Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter